Abstract
A 31-year-old who had a history of delayed puberty and then developed amenorrhea after stopping birth control pills was found to have a macroprolactinoma. Cabergoline therapy resulted in normalization of prolactin and menstrual periods within 6 months. The adenoma size decreased slowly, and the patient conceived. The dopamine agonist was withdrawn upon conception and restarted postpartum. Visual fields were monitored during the pregnancy which was uneventful. The diagnosis and therapy of hyperprolactinemia in a patient seeking fertility and the peri-partum management of prolactinoma during pregnancy are discussed.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Landolt AM. [Prolactin-producing pituitary adenomas as a cause of primary amenorrhea and their neurosurgical treatment]. Dtsch Med Wochenschr. 1983;108(8):298–301.
Ajmal A, Joffe H, Nachtigall LB. Psychotropic-induced hyperprolactinemia: a clinical review. Psychosomatics. 2014;55(1):29–36.
Shin SH, et al. Morphine can stimulate prolactin release independent of a dopaminergic mechanism. Can J Physiol Pharmacol. 1988;66(11):1381–5.
Gold MS, et al. Increase in serum prolactin by exogenous and endogenous opiates: evidence for antidopamine and antipsychotic effects. Am J Psychiatry. 1978;135(11):1415–6.
Glezer A, Bronstein MD. Prolactinomas, cabergoline, and pregnancy. Endocrine. 2014;47(1):64–9.
Melmed S, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273–88.
Vilar L, Fleseriu M, Bronstein MD. Challenges and pitfalls in the diagnosis of hyperprolactinemia. Arq Bras Endocrinol Metabol. 2014;58(1):9–22.
St-Jean E, Blain F, Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol (Oxf). 1996;44(3):305–9.
Moraes AB, et al. Giant prolactinomas: the therapeutic approach. Clin Endocrinol (Oxf). 2013;79(4):447–56.
Brue T, Castinetti F. The risks of overlooking the diagnosis of secreting pituitary adenomas. Orphanet J Rare Dis. 2016;11(1):135.
Faje A, Nachtigall L. Current treatment options for hyperprolactinemia. Expert Opin Pharmacother. 2013;14(12):1611–25.
Biller BM, et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab. 1996;81(6):2338–43.
Molitch ME, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab. 1985;60(4):698–705.
Colao A, et al. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab. 1997;82(11):3574–9.
Webster J, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med. 1994;331(14):904–9.
Donegan D, et al. Surgical outcomes of prolactinomas in recent era: results of a heterogenous group. Endocr Pract. 2017;23(1):37–45.
Wilson CB. Surgical management of pituitary tumors. J Clin Endocrinol Metab. 1997;82(8):2381–5.
Pashtan I, Oh KS, Loeffler JS. Radiation therapy in the management of pituitary adenomas. Handb Clin Neurol. 2014;124:317–24.
Ono M, et al. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab. 2010;95(6):2672–9.
Sarwar KN, et al. The prevalence and natural history of pituitary hemorrhage in prolactinoma. J Clin Endocrinol Metab. 2013;98(6):2362–7.
Watt A, Pobereskin L, Vaidya B. Pituitary apoplexy within a macroprolactinoma. Nat Clin Pract Endocrinol Metab. 2008;4(11):635–41.
Briet C, et al. Pituitary apoplexy. Endocr Rev. 2015;36(6):622–45.
Molitch ME. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol. 2015;172(5):R205–13.
Maiter D, Delgrange E. Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol. 2014;170(6):R213–27.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Enakuaa, S., Nachtigall, L.B. (2018). Macroprolactinoma: Diagnosis and Management in a Patient with Infertility. In: Nachtigall, L. (eds) Pituitary Tumors. Springer, Cham. https://doi.org/10.1007/978-3-319-90909-7_1
Download citation
DOI: https://doi.org/10.1007/978-3-319-90909-7_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-90907-3
Online ISBN: 978-3-319-90909-7
eBook Packages: MedicineMedicine (R0)